Allwright M, Guennewig B, Hoffmann AE, Rohleder C, Jieu B, Chung LH, Jiang YC, Lemos Wimmer BF, Qi Y, Don AS, Leweke FM, Couttas TA. ReTimeML: a retention time predictor that supports the LC-MS/MS analysis of sphingolipids. Sci Rep. 2024 14(1):4375.
Couttas TA, Boost C, Pahlisch F, Sykorova EB, Mueller JK, Jieu B, Leweke JE, Dammann I, Hoffmann AE, Loeffler M, Grimm O, Enning F, Flor H, Meyer-Lindenberg A, Koethe D, Rohleder C, Leweke M. Dose-dependent effects of oral cannabidiol and delta-9-tetrahydrocannabinol on serum anandamide and related N-acylethanolamines in healthy volunteers. BMJ Ment Health. 2024 27(1)
Dammann I, Rohleder C, Leweke FM. Cannabidiol and its Potential Evidence-Based Psychiatric Benefits - A Critical Review. Pharmacopsychiatry. 2024 57(3):115-132. Epub 2024 Jan 24.
Jieu B, Sykorova EB, Rohleder C, Marcolini E, Hoffmann AE, Koethe D, Leweke FM, Couttas TA. Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol. Psychiatry Res. 2024 339:116005. Epub 2024 Jun 4.
Scott EM, Shin M, Banati RB, Brown D. A., Koethe D, Leweke FM, Rohleder C, Hickie IB. Neuroimmune-mediated neuropsychiatric syndromes: perspectives for standardised diagnostics and personalised care. Res Dir Depr. 2024 1:e25.